Skip to content
Medical Health Aged Care

Victorian Opposition’s free MenB vaccine commitment ‘will save young lives’: GPs

Royal Australian College of GPs 2 mins read

The Royal Australian College of GPs (RACGP) has welcomed a commitment from the Victorian Liberals and Nationals to provide free vaccinations against deadly meningococcal B infections.

Meningococcal B infections can cause meningitis (brain inflammation) or septicaemia (blood poisoning) resulting in rapid death or disability including brain damage and limb loss. Victoria has recorded 14 cases of meningococcal B this year.

RACGP Victoria again called for the State Government to match other jurisdictions by providing free vaccines to at-risk groups following the passing of 16-year-old Levi Syer, who died shortly after developing symptoms of the deadly bacterial infection.

While the meningococcal ACWY vaccine is free under the National Immunisation Program for all children and young people, the vaccine against the B strain is not provided for all children and for most requires an out-of-pocket payment of $110–150 per dose. Both are recommended in the Australian Immunisation Handbook.

RACGP Vicotria Chair Dr Anita Muñoz praised the commitment from the Opposition.

“We’ve seen how much of a difference this protection makes just two months ago with the death of Levi Syer,” she said.

“Meningitis isn’t predictable, but it is preventable through vaccination. It shouldn’t be on families to ensure they’re protected against all strains – that’s why we’ve got a health system.

“Levi died about a day after he first fell ill. That’s shockingly common for meningococcal B infections. Making the MenB vaccine accessible for all Victorians will save young lives.

“Our children and young people deserve better. Other jurisdictions have provided this protection free of charge, but Victorians have to seek it out and pay out of pocket.”

Free meningococcal B vaccines for those aged two and under and every teen aged 15–19 has been part of the RACGP’s longstanding advocacy.

“This disease kills about one in 10 patients and leaves up to 20% of those who survive with permanent brain damage, hearing loss or a learning disability,” Dr Muñoz said.

“Since the MenC and then MenACWY vaccines were introduced, meningococcal B has become the leading cause of meningococcal disease, accounting for 83% of cases. Yet we’ve got a safe and effective MenB vaccine.

“We can and should get to zero deaths. We know how to do it, and we’ve sadly seen why we should.”

~ENDS


About us:

The Royal Australian College of General Practitioners (RACGP) is the peak representative organisation for general practice, the backbone of Australia’s health system. We set the standards for general practice, facilitate lifelong learning for GPs, connect the general practice community, and advocate for better health and wellbeing for all Australians.

Visit www.racgp.org.au. To unsubscribe from RACGP media releases, click here.


Contact details:

John Ronan
Senior Media Advisor

Stuart Winthrope
Media Advisor

Kevin Diggerson
Public Affairs Manager

Contact: 03 8699 0992[email protected]

Follow us on X and Facebook.

Media

More from this category

  • Medical Health Aged Care
  • 09/01/2026
  • 23:40
Dark Horse Consulting Group

Bruder Consulting & Venture Group to become Dark Horse Consulting Regenerative Medicine

WALNUT CREEK, Calif. and NEW YORK, Jan. 09, 2026 (GLOBE NEWSWIRE) -- Dark Horse Consulting Group (“DHCG” or “the Group”), a leader in strategic and operational biotherapeutics consulting, is pleased to announce the acquisition of Bruder Consulting & Venture Group (“Bruder” or “BCVG”), a strategic advisory and consulting firm with a global footprint in biotech and biopharma, known for their expertise in the discovery, development, clinical design, and regulatory approval process of biologics, devices and combination products in the orthopedic, wound care, and plastic & reconstructive surgery markets. BCVG is now a department within Dark Horse Consulting (DHC) known as…

  • Medical Health Aged Care
  • 09/01/2026
  • 23:11
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.

Biocytogen and Acepodia Expand Collaboration Through Option-based Evaluation Framework for First-in-Class Bispecific and Dual-Payload ADCs (BsAD2C)

Expanded collaboration builds on Acepodia and Biocytogen’s recent co-development efforts to evaluate selected bispecific antibody and dual-payload ADC programs   BEIJING & ALAMEDA, Calif.…

  • Contains:
  • Medical Health Aged Care
  • 09/01/2026
  • 17:11
MRM Health NV

MRM Health Secures FDA IND Clearance to Launch its Phase 2b Trial of MH002 in Mild-to-Moderate Ulcerative Colitis

MH002 is currently the most advanced Live Biotherapeutic Product (LBP) based on a rationally-designed combination of disease specific bacteria (microbial consortia), for the treatment…

  • Contains:

Media Outreach made fast, easy, simple.

Feature your press release on Medianet's News Hub every time you distribute with Medianet. Pay per release or save with a subscription.